Skip to main content
. Author manuscript; available in PMC: 2021 Nov 22.
Published in final edited form as: Shock. 2021 May 1;55(5):676–685. doi: 10.1097/SHK.0000000000001641

Fig. 1. Study design.

Fig. 1.

(A) Floxed IL-6 mice (IL-6lox/lox) were bred with (B) alpha actin merCREmer mice (HSA-CreERT2/−) to form (C) homozygote floxed SkmIL-6+/+ mice with a heterozygote HSA-CreErt/+/−. Groups B and C were then randomly divided into raloxifene treatment (to induce Cre) or vehicle treatment to produce a total of four experimental groups. Comparisons within group B were used to test for effects of raloxifene treatment and CRE induction. Comparisons in Group C were used to test for effects of SkmIL-6 knockdown. SkmIL-6 indicates skeletal muscle interleukin-6, IL; HSA, human skeletal muscle α-actin promoter.